Who
5AM Partners VI, LLC
10% owner
Company insider
Files Form 4 as: 10% owner, Latigo Biotherapeutics; 10% owner, CAMP4 Therapeutics; 10% owner, Artiva Biotherapeutics; 10% owner, CinCor Pharma; 10% owner, 5:01 Acquisition.
In numbers
- Trades disclosed
- 19
- Buys
- 2
- Sells
- 0
- Bought
- $28.0M
- Sold
- $0
- Companies
- 5
- Companies where not an officer
- 5
- First trade
- 16 Oct 2020
- Last trade
- 10 Aug 2026
- Last filed
- 12 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 10 Aug 2026filed 12 Aug 2026 | LTGO Latigo Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —3,152,305 at $0.00 | filing |
| 10 Aug 2026filed 12 Aug 2026 | LTGO Latigo Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —1,823,238 at $0.00 | filing |
| 10 Aug 2026filed 12 Aug 2026 | LTGO Latigo Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —866,018 at $0.00 | filing |
| 10 Aug 2026filed 12 Aug 2026 | LTGO Latigo Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —1,484,401 at $0.00 | filing |
| 10 Aug 2026filed 12 Aug 2026 | LTGO Latigo BiotherapeuticsBiotechnology | SEC FORM 4 Code C | —4,975,543 | filing |
| 10 Aug 2026filed 12 Aug 2026 | LTGO Latigo BiotherapeuticsBiotechnology | SEC FORM 4 Code C | —2,350,419 | filing |
| 3 Aug 2026filed 5 Aug 2026 | CAMP CAMP4 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code P | $4.9M3,179,558 at $1.53 | filing |
| 22 Jul 2024filed 24 Jul 2024 | ARTV Artiva Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —843,592 | filing |
| 22 Jul 2024filed 24 Jul 2024 | ARTV Artiva Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —214,692 | filing |
| 22 Jul 2024filed 24 Jul 2024 | ARTV Artiva BiotherapeuticsBiotechnology | SEC FORM 4 Code C | —1,058,284 | filing |
| 22 Jul 2024filed 24 Jul 2024 | ARTV Artiva BiotherapeuticsBiotechnology | SEC FORM 4 Code J | $1.2M112,966 at $10.20 | filing |
| 22 Jul 2024filed 24 Jul 2024 | ARTV Artiva BiotherapeuticsBiotechnology | SEC FORM 4 Code J | $3.6M348,721 at $10.20 | filing |
| 22 Jul 2024filed 24 Jul 2024 | ARTV Artiva BiotherapeuticsBiotechnology | SEC FORM 4 Bought | $10.0M833,333 at $12.00 | filing |
| 15 Aug 2022filed 17 Aug 2022 | CinCor Pharma | SEC FORM 4 Bought | $3.4M112,667 at $30.00 | filing |
| 15 Aug 2022filed 17 Aug 2022 | CinCor Pharma | SEC FORM 4 Bought | $14.6M487,333 at $30.00 | filing |
| 30 Nov 2020filed 1 Dec 2020 | 5:01 Acquisitionoption or derivative | SEC FORM 4 Code J | —235,932 at $0.00 | filing |
| 17 Nov 2020filed 18 Nov 2020 | 5:01 Acquisitionoption or derivative | SEC FORM 4 Code J | —30,000 at $0.00 | filing |
| 16 Oct 2020filed 20 Oct 2020 | 5:01 Acquisitionoption or derivative | SEC FORM 4 Code J | —90,000 at $0.00 | filing |
| 16 Oct 2020filed 20 Oct 2020 | 5:01 Acquisition | SEC FORM 4 Code J | $3.6M360,000 at $10.00 | filing |
News
No headline names them, or the companies they trade most, lately.